More: American Pain Society (APS) 27th Annual Scientific Meeting

APS 2008: Balancing Access and Risk in Acute Pain Management CME

May 8 - 10, 2008, Tampa, Florida

Author Information and Disclosures

This activity is not sanctioned by, nor a part of, the American Pain Society.

Conference news does not receive grant support and is produced independently.

Release Date: June 27, 2008; Valid for credit through June 27, 2009

Credits Available
Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

Legal Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Pain Society. These materials and the related activity are not sanctioned by the American Pain Society or the commercial supporter of the conference and do not constitute an official part of that conference.

Copyright © 2008 Medscape.
PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals Inc
Learning Objectives
Upon completion of this activity, participants will be able to:
  1. Explain the legitimate role of controlled substances for acute pain management
  2. Examine the unique aspects of acute pain management in different clinical settings
  3. Put into perspective clinicians fear of aggressively managing acute pain
  4. Discuss strategies to maximize treatment of acute pain
Authors and Disclosures

Steven D. Passik, PhD
Disclosure: Steven D. Passik, PhD, has disclosed that he has served as a consultant or speaker for Cephalon, Ligand, Eli Lilly, PriCara, and King Pharmaceuticals. Dr. Passik has also disclosed that he has received grants for research from Cephalon and Ligand.


Perry G. Fine, MD
Disclosure: Perry G. Fine, MD, has disclosed that he has served on the advisory board for Alpharma, Abbott, Cephalon, GlaxoSmithKline, Lilly, Merck, Ortho-McNeil, and Wyeth


Bill H. McCarberg, MD
Disclosure: Bill H. McCarberg, MD, has disclosed that he has served on the speaker's bureau for Endo, Pfizer, Eli Lilly, Merck, PRICARA, Alpharma, King, and Cephalon.


Knox H. Todd, MD, MPH
Disclosure: Knox H. Todd, MD, MPH, has disclosed that he has served as an advisor or consultant to XenoPort, Johnson & Johnson, Abbott Labs, and Alpharma. Dr. Todd has also disclosed that he has received grants for clinical research from Baxter Healthcare.


Darlene Foschini-Field, PhD
Disclosure: Darlene Foschini-Field, PhD, has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.